Skip to content
Screener

Fulgent Genetics, Inc. FLGT Laboratory Services — Research And Development Expense

Other segment segments

Therapeutic Development
$4.18M+4.7%

Similar metrics at other companies

Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Viasat logo
VSATCommunication Services — Research And Development Expense
$28.4M+47.9%
Innoviva, Inc. logo
INVAExternal Services — Research And Development Expense
$2.46M-63.7%
Eve Holding logo
EVEXService Support — Research And Development Expense
$2.55M+91.1%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Axe Compute Inc. logo
AGPUDrug Discovery Services — Research And Development Expense
$2.14M+283%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$526.64M-16.5%
Enterprise value$511.45M-6.7%
P/S1.6×-0.4×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 7:08 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-199065
Three Months Ended March 31, 2026Laboratory ServicesTherapeutic DevelopmentTotal
Revenue$71,051$87$71,138
Less:
Adjusted cost of revenue48,179848,187
Adjusted research and development6,4614,17810,639
Adjusted selling and marketing11,57611,576
Adjusted general and administrative20,05235720,409
Total adjusted operating loss$(15,217)$(4,456)$(19,673)

Item 1. Financial Statements.

FAQ

What is Fulgent Genetics, Inc.'s laboratory services — research and development expense?
Fulgent Genetics, Inc. (FLGT) reported laboratory services — research and development expense of $6.46M in Q1 2026.
How has Fulgent Genetics, Inc.'s laboratory services — research and development expense changed year-over-year?
Fulgent Genetics, Inc.'s laboratory services — research and development expense increased by 31.0% year-over-year, from $4.93M to $6.46M.
What is the long-term trend for Fulgent Genetics, Inc.'s laboratory services — research and development expense?
Over 3 years (2022 to 2025), Fulgent Genetics, Inc.'s laboratory services — research and development expense has grown at a 6.9% compound annual growth rate (CAGR), from $17.72M to $21.64M.
What does laboratory services — research and development expense mean?
These are the costs incurred to develop new diagnostic tests, improve existing laboratory methodologies, and advance genetic testing technologies. This investment reflects the company's commitment to maintaining a competitive edge through innovation in the clinical diagnostics market.

Ask your AI about Fulgent Genetics, Inc.'s laboratory services — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude